Efficacy of long-term treatment with mepolizumab in severe eosinophilic asthma (case reports)
https://doi.org/10.18093/0869-0189-2019-29-5-625-631
Abstract
Two clinical cases of severe eosinophilic asthma taking long-term therapy with mepolizumab (38 and 45 months are described in the article. Both the cases demonstrate the effectiveness of the drug both in allergic and non-allergic (aspirin-induced) asthma. Significant clinical improvement was achieved in both cases under the treatment with mepolizumab during ≥ 3 years. Important results of the treatment were improvement in symptoms of severe asthma, reduction in exacerbation rate, and, additionally, overcoming corticosteroid addiction in patients. The therapy with mepolizumab was highly safe.
Supporting agencies: The authors participated in a multi-center randomized controlled study of mepolizumab supported by GlaxoSmithKline company.
About the Authors
B. A. Chernyak
Irkutsk State Medical Academy of Postgraduate Training – a branch of Russian Federal Academy of Continued Medical Education, Healthcare Ministry of Russia
Russian Federation
Russian Federation
Boris A. Chernyak - Doctor of Medicine, Professor, Head of Department of Clinical Allergology and Pulmonology, Irkutsk State Medical Academy of Postgraduate Training – a branch of Russian Federal Academy of Continued Medical Education, Healthcare Ministry of Russia.
mkr Yubileynyy 100, Irkutsk, 664079.
tel.: (9025) 68-78-70I. I. Vorzheva
Irkutsk State Medical Academy of Postgraduate Training – a branch of Russian Federal Academy of Continued Medical Education, Healthcare Ministry of Russia
Russian Federation
Russian Federation
Irina I. Vorzheva - Candidate of Medicine, Associate Professor, Department of Clinical Allergology and Pulmonology, Irkutsk State Medical Academy of Postgraduate Training – a branch of Russian Federal Academy of Continued Medical Education, Healthcare Ministry of Russia.
mkr Yubileynyy 100, Irkutsk, 664079.
tel.: (9025) 68-78-70A. F. Ivanov
Irkutsk State Medical Academy of Postgraduate Training – a branch of Russian Federal Academy of Continued Medical Education, Healthcare Ministry of Russia
Russian Federation
Russian Federation
Aleksandr F. Ivanov - Candidate of Medicine, Assistant Lecturer, Department of Clinical Allergology and Pulmonology, Irkutsk State Medical Academy of Postgraduate Training – a branch of Russian Federal Academy of Continued Medical Education, Healthcare Ministry of Russia.
mkr Yubileynyy 100, Irkutsk, 664079.
tel.: (9025) 68-78-70References
1. Wenzel S.E., Schwartz L.B., Langmack E.L. et al. Evidence that severe asthma can be divided pathologically into two inf lammatory subtypes with distinct physiologic and clinical characteristics. Am. J. Respir. Crit. Care Med. 1999; 160 (3): 1001–1008. DOI: 10.1164/ajrccm.160.3.9812110.
2. Price D.B., Rigazio A., Campbell J.D. et al. Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study. Lancet Respir. Med. 2015; 3 (11): 849–858. DOI: 10.1016/S2213-2600(15)00367-7.
3. de Groot J.C., Storm H., Amelink M. et al. Clinical profile of patients with adult-onset eosinophilic asthma. ERJ Open Res. 2016; 2 (2): pii: 00100-2015.4. DOI: 10.1183/23120541.00100-2015.
4. Schleich F.N., Chevremont A., Paulus V. et al. Importance of concomitant local and systemic eosinophilia in uncontrolled asthma. Eur. Respir. J. 2014; 44 (1): 97–108. DOI: 10.1183/09031936.00201813.
5. Buhl R., Humbert M., Bjermer L. et al. Severe eosinophilic asthma: a roadmap to consensus. Eur. Respir. J. 2017; 49 (5): pii: 1700634. DOI: 10.1183/13993003.00634-2017.
6. Chung K.F. Precision medicine in asthma: linking phenotypes to targeted treatments. Curr. Opin. Pulm. Med. 2018; 24 (1): 4–10. DOI: 10.1097/MCP.0000000000000434.
7. Pelaia C., Vatrella A., Busceti M.T. et al. Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab. Drug Des. Devel. Ther. 2017; 11: 3137–3144. DOI: 10.2147/DDDT.S150656.
8. Haldar P., Brightling C.E., Hargadon B. et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N. Engl. J. Med. 2009; 360: 973–984. DOI: 10.1056/NEJMoa0808991.
9. Pavord I.D., Korn S., Howarth P. et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicenter, double-blind, placebo-controlled trial. Lancet. 2012; 380 (9842): 651–659. DOI: 10.1016/S0140-6736(12)60988-X.
10. Ortega H.G., Liu M.C., Pavord I.D. et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N. Engl. J. Med. 2014; 371: 1198–1207. DOI: 10.1056/NEJMoa1403290.
11. Bel E.H., Wenzel S.E., Thompson P.J. et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N. Engl. J. Med. 2014; 371: 1189–1197. DOI: 10.1056/NEJMoa1403291.
12. Albers F.C., Price R.G., Smith S.G., Yancey S.W. Mepolizumab efficacy in patients with severe eosinophilic asthma receiving different controller therapies. J. Allergy Clin. Immunol. 2017; 140 (5): 1464–1466.e4. DOI: 10.1016/j.jaci.2017.06.010.
13. Chernyak B.A., Vorzheva I.I. [Efficacy and safety of mepolizumab in severe eosinophilic asthma: a review]. Farmateka. 2019; 11: 10–20. DOI: 10.18565/pharmateca.2019.11.10-20 (in Russian).
14. Lugogo N., Domingo C., Chanez P. et al. Long-term efficacy and safety of mepolizumab in patients with severe eosinophilic asthma: a multi-center, open-label, phase IIIb study. Clin. Ther. 2016; 38 (9): 2058–2070.е1. DOI: 10.1016/j.clinthera.2016.07.010.
15. Khatri S., Moore W., Gibson P.G. et al. Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma. J. Allergy Clin. Immunol. 2019; 143 (5): 1742–1751.е7. DOI: 10.1016/j.jaci.2018.09.033.
16. Gevaert P., van Bruaene N., Cattaert T. et al. Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis. J. Allergy Clin. Immunol. 2011; 128 (5): 989–995.е8. DOI: 10.1016/j.jaci.2011.07.056.
17. Bachert C., Sousa A.R., Lund V.J. et al. Reduced need for surgery in severe nasal polyposis with mepolizumab: randomized trial. J. Allergy Clin. Immunol. 2017; 140 (4): 1024–1031.е14. DOI: 10.1016/j.jaci.2017.05.044.
18. Tuttle K.L., Buchheit K.M., Laidlaw T.M., Cahill K.N. A retrospective analysis of mepolizumab in subjects with aspirin-exacerbated respiratory disease. J. Allergy Clin. Immunol. Pract. 2018; 6 (3): 1045–1047. DOI: 10.1016/j.jaip.2018.01.038.
19. Cavaliere C., Incorvaia C., Frati F. et al. Recovery of smell sense loss by mepolizumab in a patient allergic to Dermatophagoides and affected by chronic rhinosinusitis with nasal polyps. Clin. Mol. Allergy. 2019; 17: 3. DOI: 10.1186/s12948-019-0106-2.
20. Sánchez-Jareño M., Barranco P., Romero D. et al. Severe eosinophilic allergic asthma responsive to mepolizumab after failure of 2 consecutive biologics. J. Investig Allergol. Clin. Immunol. 2019; 29 (1): 79–81. DOI: 10.18176/j.iaci.0340.
Review
For citations:
Chernyak B.A., Vorzheva I.I., Ivanov A.F. Efficacy of long-term treatment with mepolizumab in severe eosinophilic asthma (case reports). PULMONOLOGIYA. 2019;29(5):625-631. (In Russ.) https://doi.org/10.18093/0869-0189-2019-29-5-625-631
Views:
1531
Email this article 